Optoacoustic technology has been proven in animal and human testing. We have 7 issued patents protecting the technology and its applications and are continuing to build our IP portfolio. The FDA has classified this as a Class II non-significant risk device.

How Optoacoustics Works

  1. Light pulses into blood in a vessel
  2. Blood hemoglobin absorbs light & emits ultrasound in proportion to concentration in the vessel
  3. Ultrasound wave travels without scattering and arrives at specific time proportional to blood vessel depth
  4. Sensor detects ultrasound
  5. Software determines location, size, and oxygenation of blood in the vessel

The Optoacoustic Advantage

Other oximeters based on NIRS can only measure a mixture of light from arteries, veins, capillaries, muscle and other absorbing chromophores in a large cone of tissue.

Our optoacoustic technology is better because it provides:

  • Direct measurement of cerebral venous oxygenation with high spatial resolution.
  • Absolute, accurate measurements of blood oxygenation.
  • Continuous, real-time monitoring.

Platform Technology

Optoacoustics is a platform technology with several applications in the healthcare market. We estimate the total US market for optoacoustics to be $5.2B ($12.9B worldwide). Of that, pediatrics (neonatal, fetal, cardiac surgery) represents $1.1B (8.5 million measurements). The remaining $4.1B market size is attributable to adult cerebral venous oxygenation (TBI, stroke, cardiac surgery), central venous oxygenation (shock, sepsis, trauma), and hemoglobin concentration monitoring (anemia, blood loss).

Optoacoustics is a Platform Technology